
Opinion|Videos|June 6, 2024
Real-World Insights: Navigating Cardiac Myosin inhibitors in Practice
Author(s)Anjali Tiku Owens, MD
Anjali Tiku Owens, MD, shares insights into how their institution or clinic implements the Risk Evaluation and Mitigation Strategy (REMS) program for mavacamten, detailing the requirements and responsibilities of the patient in the process. Additionally, the expert draws upon their real-world experience with the cardio myosin inhibitor (CMI) in clinical practice, providing valuable perspectives on the practical application of this novel drug class.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Libre Duo 10 Day Authorized as First Glucose-Ketone Monitor for Diabetes
2
Psoriasis Awareness & Action Month: New Oral Drugs and Other Developments
3
FDA Approves First-in-Class RAS Inhibitor for Metastatic Pancreatic Cancer
4
TMS Sessions Reduced From 38 Minutes to 3, With Jonathan Downar, MD, PhD
5








































































